Feng Chi Chen
Affiliation: National Health Research Institutes
Chen F, Lee P. Inter Partes Review: Patent Killer No More?. Trends Biotechnol. 2019;: pubmed publisher
..However, recent changes in the IPR system foretell a tectonic shift in the landscape. Here we summarize these major changes and discuss the implications for the biopharmaceutical community. ..
Chen F. China: The Next Pharmacy of the World?. Trends Pharmacol Sci. 2018;39:843-848 pubmed publisher
..Here, I briefly discuss how this guideline may change the industry landscape, and its associated challenges and opportunities. ..
Chen F, Chuang T. Different alternative splicing patterns are subject to opposite selection pressure for protein reading frame preservation. BMC Evol Biol. 2007;7:179 pubmed
..Therefore, we suggest that evolutionary analyses of AS should take into consideration the effects of different splicing patterns and the joint effects of multiple AS events. ..
Chen F, Chuang T, Lin H, Hsu M. The evolution of the coding exome of the Arabidopsis species--the influences of DNA methylation, relative exon position, and exon length. BMC Evol Biol. 2014;14:145 pubmed publisher
..thaliana coding exons. Furthermore, CpG methylation is correlated with exonic evolutionary rates differentially between A. thaliana and animals, and may have served different biological roles in the two lineages. ..
Chen F. Divided Infringement in the Limelight of the Patent Battle Field. Trends Biotechnol. 2016;34:771-773 pubmed publisher
..However, in the USA, joint implementation may render diagnostic patents unenforceable in light of recent court opinions. Here, I explain how inappropriate claim drafting may render a diagnostic patent vulnerable to joint implementation. ..
Chen F, Yeh K. Invalidation of Atorvastatin Patent Highlights Complex Chinese Patent Law. Trends Pharmacol Sci. 2016;37:883-886 pubmed publisher
..Here, we discuss the particularities in patent litigation in China worth attention from the community. ..